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Abstract  
Purpose: This study aimed to report the characteristics and treatment outcome of 8 patients with solitary osseous plasmacytoma of 
the head and neck with special focus on mandibular plasmacytoma.  
Materials and Methods: The study was conducted on 8 patients with solitary osseous plasmacytoma of the head and neck who 
were treated at two academic tertiary referral hospitals between 1999 and 2010. All the patients were treated with curative intent. 
Four patients (50%) were primarily treated with radiotherapy alone at initial diagnosis, one patient (12.5%) underwent surgery 
alone, and 3 patients (37.5%) were treated with gross tumor resection followed by radiotherapy. The median total radiation dose 
was 46 (range 30-50) GY.  
Results: There were 4 women and 4 men aging from 37 to 73 years, with a median and mean age of 52 years at diagnosis. Pain (in 
7 cases) and swelling (in 5 cases) were the most common presentations. Mandible (in 4 cases) was the most frequent primary site. 
The median tumor size was 4.8 (range 3.5-6) cm. After a median follow-up of 44 months (range 27-79 months), 5 patients are 
alive and without disease, one is alive with multiple myeloma, and two died of multiple myeloma.  
Conclusion: Solitary osseous plasmacytomas of the head and neck have a propensity to involve the mandibular bones and 
response well to effective local treatments of radiotherapy and/or surgery. These Patients tend to progress to multiple myeloma 
even years after the initial treatment. 
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Introduction 
Plasma cell neoplasms are a group of 
hematologic malignancies characterized by the 
neoplastic single clone proliferation of plasma 
cells, classically producing a monoclonal 
immunoglobulin [1]. These neoplasms can 
involve a single site which are defined as 
solitary plasmacytoma or multiple sites which 
are defined as multiple myeloma. Solitary 
plasmacytomas account for 5% to 10% of all 
plasma cell neoplasms which are characterized 
by the presence of a plasmacytoma in the 
absence of evidences suggesting systemic 
myeloma, such as multiple osteolytic lesions 
[1-3]. Solitary osseous plasmacytoma usually 
occurs in the sixth to seventh decades of life 
with a median age of 55 years at diagnosis. It 
is 2-3 times more common in males [1,4,5]. 
Approximately two thirds of solitary 
plasmacytomas occur in the bone, which most 
frequently involve the axial skeleton, whereas 
the remaining one-third of the cases are 
extramedullary plasmacytomas, which most 
commonly present in the upper aerodigestive 
tract. Solitary plasmacytoma of the mandible is 
very rare and to date, only 52 cases have been 
reported [6-8]. Progression to multiple 
myeloma is an ominous outcome that is more 
likely to occur in osseous plasmacytoma 
compared to extramedullary plasmacytoma. 
Approximately 50-75% of solitary osseous 
plasmacytomas ultimately progress to multiple 
myeloma [1-3,5,9,10]. Patients with head and 
neck solitary osseous plasmacytoma usually 
present with pain, bone destruction, and 
pathologic fracture. Diagnostic evaluation 
includes a complete blood count, whole 
skeletal radiographic survey, serum and urine 
protein electrophoresis, quantitative 
immunoglobulin levels, urinary protein 
excretion in 24 hours, and bone marrow 
aspiration and biopsy [1,10]. Recent studies 
suggest that a positron emission tomography 
combined with Computed Tomography 
(PET/CT) scan or entire spine and pelvis 
Magnetic Resonance Imaging (MRI) may be 
more accurate than a conventional x-ray bone 
survey for detecting other foci of 
plasmacytomas [11]. This study aimed to 
report the characteristics and treatment 
outcome of 8 patients with solitary osseous 
plasmacytoma of the head and neck with 
special focus on mandibular plasmacytoma.   
Materials and Methods 
The present study was conducted on 8 patients 
with solitary osseous plasmacytoma of the 
head and neck who were treated at two 
academic tertiary referral hospitals between 
1999 and 2010. The study was approved by the 
Clinical Research Ethics Committee of Shiraz 
University of Medical Sciences, Shiraz, Iran in 
accordance with The Code of Ethics of the 
World Medical Association (Declaration of 
Helsinki) for experiments involving humans. 
In this study, solitary osseous plasmacytoma 
was defined as a single area of bone 
destruction due to neoplastic plasma cells 
(Figure 1), no evidence of M protein in serum 
and/or urine, normal skeletal survey, and 
normal bone marrow or less than 5% plasma 
cell infiltration in the bone marrow without 
evidence of multiple myeloma features 
(anemia, renal insufficiency, increased calcium, 
or multiple bone lesions). Nonetheless, the 
patients with small serum M component and 
post-therapy normalized serum levels were not 
excluded. In addition, Immunohistochemical 
staining was performed for kappa and lambda 
light chains in 5 cases (Figure 2 and 3). All the 
patients were treated with curative intent. Four 
patients (50%) were primarily treated with 
radiotherapy alone at initial diagnosis, one 
patient (12.5%) underwent surgery alone, and 
3 patients (37.5%) were treated with gross 
tumor resection followed by radiotherapy. The 
median total radiation dose was 46 (range 
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30-50) GY.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Plasmacytoma shows Lambda light chain restriction (case 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Plasmacytoma shows Lambda light chain restriction (case 8).  
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Figure 3 Plasmacytoma shows Kappa light chain restriction (case 5).  
 
Results 
 There were 4 women and 4 men aging from 
37 to 73 years, with a median and mean age of 
52 years at diagnosis. Pain (87.5%) and 
swelling (62.5%) were the most common 
presentations (Table 1) and mandible (50%) 
was the most frequent primary site. Besides, 
pain, mass and swelling, teeth loosening and 
infection, and mandibular numbness were the 
signs and symptoms of 4 patients with 
mandibular plasmacytoma (Table 2). A 
well-circumscribed osteolytic lesion was the 
most imaging finding in all cases (Figures 4-6). 
This finding was observed in plain x-ray 
images in the mandibular angles (2 cases), 
ramus (one case), and molar region (one case) 
(Figure 7). The median tumor size of 8 patients 
was 4.8 (range 3.5-6) cm. Two patients (cases 
3 and 5) had small serum M components which 
were normalized after the initial treatment. In 
5 out of the 8 patients (cases of 1, 4, 5, 7, and 
8) who had Immunohistochemical staining, 
monoclonal Lambda or Kappa light chain 
expression was demonstrated. The median 
follow-up was 44 (range 27-79) months. 
Following the initial radiotherapy and/or 
surgery, all the patients achieved good local 
control. Also, none of the patients developed 
local recurrent disease; however, three out of 
the 8 patients (37.5%) developed multiple 
myeloma after an average time of 21 (with a 
range of 9 to 34) months from the initial local 
treatment. These patients (cases of 5, 6, and 7) 
were subsequently treated with chemotherapy 
with or without thalidomide and bortezomib; 
two patients (cases of 5 and 7) died 16 and 31 
months after developing myeloma (49 and 58 
months after the initial diagnosis) and the 
other remaining patient is alive and receiving 
systemic therapy for his multiple myeloma 
(Table 2).  
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Table 1 Patients’ characteristics and treatment outcome 
Case 
Age 
(yr) 
/sex 
Tumor 
location 
Tumor 
size 
(cm) 
First 
presentation 
F.U 
(month) 
Treatment 
Dose 
of RT 
(Gy) 
PTMM 
Survival 
status 
1 37/F Mandible 
5 
Pain and 
swelling 
39 RT alone 50 - ANED 
2 48/F Mandible 
5 
Pain and 
swelling 
66 Surgery 
alone 
- - ANED 
3 61/F Mandible 
6 
pain 79 RT  
alone 
46 - ANED 
4 71/F Mandible 
5 
pain and 
swelling 
35 GTR + 
RT 
40 - ANED 
5 52/M Cervical 
spine 4 
pain 33 RT  
alone 
30 + DOD 
6 41/M Cervical 
spine 3.5 
pain 44 RT alone 40 + AWD 
7 45/M Occipital 
bone 4.5 
Mass and 
swelling 
27 GTR + 
RT 
48 + DOD 
8 60/M Frontal 
bone 5 
Pain and 
swelling 
62 GTR + 
RT 
50 - ANED 
 
 
 
Figure 4 CT scan without (A) and with (B) contrast of the skull shows a large well defined osteolytic 
lesion in frontal skull bone (case 8).  
 
 
Table 2 Presenting signs and symptoms for 4 patients with mandibular plasmacytoma  
 
A B 
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Signs and symptoms NO 
Pain 4/4 
Mass or swelling  3/4 
Teeth loosening  1/4 
Infected teeth 1/4 
Numbness 1/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 CT scan of the cervical spine shows a well demarcated lytic lesion in C2 vertebral body (case 
6). 
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Figure 6 Sagittal gadolinium-enhanced T1-weighted MR images of the neck shows inhomogenously 
enhancing soft-tissue mass in the C2 vertebral body (case 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Panoramic radiograph shows osteolytic lesion in right molar region of the mandibular bone 
with intraoral soft tissue component (case 3).  
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Discussion  
The majority (83%) of the cases with solitary osseous 
plasmacytoma occur in the axial skeleton and skull and 
facial bones are rare locations for these neoplasms 
accounting for approximately 10-25% of all the primary 
sites for solitary osseous plasmacytoma [4,9,12]. There 
are very limited data regarding the solitary osseous (or 
bone) plasmacytoma of the head and neck in the 
literature. Moreover, most available reports include head 
and neck primary sites in the context of all solitary 
plasmacytoma and are usually mixed with the 
extramedullary plasmacytoma [2,4,5,12-18]. These 
neoplasms usually occur in the sixth and seventh decades 
of life. In the literature review, the median age of 946 
patients in 4 studies was 62.5 (range 54-65) years 
[2,12,13,15]. In the present study, on the other hand, the 
median age of the patients was 52 years, which is about 
10 years lower than that is reported in the literature. 
There is a sex-specific susceptibility difference to solitary 
osseous plasmacytoma. In all the reported series in the 
literature, men comprise a higher proportion of solitary 
osseous plasmacytoma sufferers compared to women, 
with a mean male/female ratio of 1.75 (range from 1.66 
to 6.3) in 3 studies including 886 patients [2,12,13]. In 
the present study, there was no sex predilection which is 
not consistent with the average range of the literature 
review. Maxilla, skull, cervical spine, and mandibles 
were the most common primary sites for head and neck 
plasmacytoma in large reported series [2,4,12,16,19,20]. 
In 2003, Lae et al. reported clinicopathologic 
characteristics of large series of 33 cases with solitary 
osseous plasmacytoma (21 cases) or secondary myeloma 
involvement (12 cases) of jaw that were treated at the 
Mayo Clinic from 1923 to 1995. Mandible was the 
involved bone in five (24%) cases of solitary 
plasmacytoma and 5 cases (42%) of secondary myeloma 
involvement [19]. Ozsahin et al. reported a large series of 
206 cases with solitary osseous plasmacytoma. Cervical 
spine, maxillary bone, and skull were the most common 
locations in head and neck region [12]. In 2011, Agostini 
et al. systematically reviewed and collected all the case 
reports and case series describing solitary plasmacytoma 
of the jaw in English language through PubMed from 
1948 to 2010. They found only 50 cases of solitary 
plasmacytoma of the mandible [6]. Mandible accounts 
for less than 5% of all solitary osseous plasmacytomas 
[2,4,6,12,16,19]. In the literature, the peak age and sex 
ratio of solitary mandibular plasmacytoma was similar to 
the other primary sites [6,19]. In our series, the patients’ 
mean age was 54.3, which is consistent with other 
reports; however, all the patients were female that is on 
the contrary to other series in which male/female ratio 
was 2.5:1 [6,19,21].  
Mandibular body, ramus, angle, molar, and premolar 
region were the most common locations in the reported 
series. These locations are consistent with bone marrow 
rich area in the mandible [6,19]. The involved area in our 
series also showed similar locations. Painful or painless 
swelling with a few weeks to several months duration 
was the most frequent signs and symptoms in the 
literature. On the other hand, infected or loose teeth, 
facial numbness, and paresthesia were reported as less 
frequent presentations [6,19,21]. Pain and swelling were 
the most common presentations in our series.  
In imaging studies, mandibular plasmacytoma usually 
presented with well-circumscribed lytic lesion or 
destructive mass with soft tissue component with or 
without pathologic mandibular fracture [6,19,21,22]. In 
this series, all the patients presented with destructive 
mandibular mass with soft tissue component in 3 cases 
and pathologic fracture in the remaining patient. 
Radiologic differential diagnoses include infections, 
benign cysts, hyperparathyroidism, metastases, other rare 
primary malignant tumors, and granulomatous disease, 
such as Langerhans cell histiocytosis [23-27]. 
Given the rarity of this entity, there is no consensus 
regarding the standard treatment for the patients with 
solitary mandibular plasmacytoma. Both surgery and 
radiotherapy have demonstrated effective long-term local 
control in the literature. Surgical resection may be 
considered in the cases with small localized disease, 
pathologic fracture, or impending mandibular fracture for 
restoring the mandibular function and avoiding long-term 
mandibular deformity and late radiation sequelae. On the 
other hand, radiotherapy may be preferred in bulky 
diseases or the cases with significant soft tissue 
component in which surgery may be associated with 
remarkable functional and cosmetic complications. In 
addition, radiotherapy is the preferred choice in the 
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patients with poor performance status not fitted for 
surgical resection. In some patients, a combined approach 
may be used for better local control and functional 
preservation [4,6,7,9,18,28]. 
Following initial local treatment, most patients achieve 
prolong local control; however, progression to multiple 
myeloma remains the most common recurrent pattern 
and worst long-term outcome in the patients with solitary 
mandibular plasmacytoma. In the study by Lae et al., the 
rate of progression to multiple myeloma was 43% after a 
median of 20.7 months [19]. However, Agostini et al. [6] 
found a rate of 12% which is significantly lower than the 
report by Lae et al. [18]; particularly compared to other 
solitary osseous plasmacytomas that progressed to 
multiple myeloma in 50-75% of the cases [5,12,21,27]. 
These discrepancies may be due to different patients’ 
follow up rather than a true disagreement. In our series, 3 
out of the 8 patients (37.5%) with head and neck solitary 
osseous plasmacytomas developed multiple myeloma.  
Conclusion 
This study suggests that solitary osseous plasmacytomas 
of the head and neck have a propensity to involve the 
mandibular bones and response well to effective local 
treatments of radiotherapy and/or surgery. These Patients 
tend to progress to multiple myeloma even years after the 
initial treatment. 
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